Compare RTX & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | AZN |
|---|---|---|
| Founded | 1934 | 1992 |
| Country | United States | United Kingdom |
| Employees | 180000 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.6B | 250.7B |
| IPO Year | 1994 | 1995 |
| Metric | RTX | AZN |
|---|---|---|
| Price | $196.90 | $169.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 12 |
| Target Price | ★ $229.17 | $206.66 |
| AVG Volume (30 Days) | ★ 4.6M | 2.5M |
| Earning Date | 10-20-2026 | 10-30-2026 |
| Dividend Yield | 1.50% | ★ 1.90% |
| EPS Growth | ★ 39.72 | N/A |
| EPS | ★ 4.96 | N/A |
| Revenue | ★ $80,738,000,000.00 | N/A |
| Revenue This Year | $9.93 | $7.80 |
| Revenue Next Year | $7.71 | $6.39 |
| P/E Ratio | $39.25 | ★ $31.91 |
| Revenue Growth | ★ 17.15 | N/A |
| 52 Week Low | $166.74 | $80.48 |
| 52 Week High | $226.88 | $212.71 |
| Indicator | RTX | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 58.28 |
| Support Level | $191.23 | $154.70 |
| Resistance Level | $205.63 | $175.04 |
| Average True Range (ATR) | 4.86 | 3.00 |
| MACD | 1.58 | 0.96 |
| Stochastic Oscillator | 88.47 | 79.01 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.